Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $837.64 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cymabay Therapeu had its IPO on 2014-02-03 under the ticker symbol CBAY.
The company operates in the Healthcare sector and Biotechnology industry. Cymabay Therapeu has a staff strength of 0 employees.
Shares of Cymabay Therapeu opened at $8.85 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $8.45 - $8.95, and closed at $8.47.
This is a -5.36% slip from the previous day's closing price.
A total volume of 1,920,769 shares were traded at the close of the day’s session.
In the last one week, shares of Cymabay Therapeu have slipped by -7.33%.
Cymabay Therapeu's Key Ratios
Cymabay Therapeu has a market cap of $837.64 million, indicating a price to book ratio of 5.7554 and a price to sales ratio of 0.
In the last 12-months Cymabay Therapeu’s revenue was $0 with a gross profit of $-43734000 and an EBITDA of $-92411000. The EBITDA ratio measures Cymabay Therapeu's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cymabay Therapeu’s operating margin was 0% while its return on assets stood at -41.71% with a return of equity of -109.78%.
In Q4, Cymabay Therapeu’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cymabay Therapeu’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cymabay Therapeu’s profitability.
Cymabay Therapeu stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0321. Its price to sales ratio in the trailing 12-months stood at 0.
Cymabay Therapeu stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $141.85 million
- Total Liabilities
- $15.44 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Cymabay Therapeu ended 2023 with $141.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $141.85 million while shareholder equity stood at $36.15 million.
Cymabay Therapeu ended 2023 with $0 in deferred long-term liabilities, $15.44 million in other current liabilities, 8000.00 in common stock, $-872857000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.29 million and cash and short-term investments were $135.49 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Cymabay Therapeu’s total current assets stands at $138.07 million while long-term investments were $0 and short-term investments were $115.19 million. Its net receivables were $0 compared to accounts payable of $1.10 million and inventory worth $0.
In 2023, Cymabay Therapeu's operating cash flow was $0 while its capital expenditure stood at $137000.
Comparatively, Cymabay Therapeu paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cymabay Therapeu stock is currently trading at $8.47 per share. It touched a 52-week high of $10.05 and a 52-week low of $10.05. Analysts tracking the stock have a 12-month average target price of $12.3.
Its 50-day moving average was $8.21 and 200-day moving average was $4.8 The short ratio stood at 3.29 indicating a short percent outstanding of 0%.
Around 34% of the company’s stock are held by insiders while 7444.2% are held by institutions.
Frequently Asked Questions About Cymabay Therapeu
Similar Industry Stocks (Biotechnology)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.